Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

492 SCOPOLAMINE
(1985): Clissold SP+, Drugs 29, 189 (transdermal patch)
Fixed eruption
(1981): Kanwar AJ+, Dermatologica 162, 378
Photosensitivity (1–10%)
Rash (sic) (10%)
Mucosal
Oral lesions (>5%)
(1985): Clissold SP+, Drugs 29, 189 (transdermal patch) (>5%)
Xerostomia (>60%)
(2006): Nachum Z+, Clin Pharmacokinet 45(6), 543 (50%)
(2002): Kranke P+, Anesth Analg 95(1), 133
(1989): Parrott AC, Aviat Space Environ Med 60(1), 1
(1985): Clissold SP+, Drugs 29, 189 (transdermal patch) (66%)
(1985): van Marion WF+, Clin Pharmacol Ther 38(3), 301
(1981): Price NM+, Clin Pharmacol Ther 29, 414
Eyes
Dilated pupils
(2006): Firth AY+, Dev Med Child Neurol 48(2), 137
Reduced visual acuity
(2006): Firth AY+, Dev Med Child Neurol 48(2), 137
Vision blurred
(1989): Parrott AC, Aviat Space Environ Med 60(1), 1
Other
Anaphylactoid reactions/Anaphylaxis
(1995): Manhart AR+, J Toxicol Clin Toxicol 33, 189 (fatal)
(1994): Watanabe F+, J Toxicol Clin Toxicol 32, 593 (fatal)
Death
Injection-site irritation (>10%)
Note: Systemic adverse effects have been reported following
ophthalmic administration
SECOBARBITAL
Synonym: quinalbarbitone
Trade names: Immenoctal; Novo-Secobarb; Secanal; Seconal
(Ranbaxy)
Indications: Insomnia
Category: Barbiturate
Half-life: 15–40 hours
Clinically important, potentially hazardous interactions
with: alcohol, anticoagulants, antihistamines, brompheniramine,
buclizine, chlorpheniramine, dicumarol, ethanolamine, imatinib,
warfarin
Reactions
Skin
Angioedema (